#Shionogi

In the third quarter of the fiscal year ending March 2026, Shionogi & Co., Ltd. achieved revenue of 360.7 billion yen (8.1% YoY increase), operating income of 148.7 billion yen (15.1% YoY increase), and quarterly profit of 158.2 billion yen (18.7% YoY increase), realizing growth in both revenue and profit.

For the third quarter of the fiscal year ending March 2026, revenue was 360,684 million yen (8.1% YoY increase), operating income was 148,739 million yen (15.1% YoY increase), and net income attributable to owners of parent for the quarter was 158,225 million yen (18.3% YoY increase). The consolidation of Torii Pharmaceutical as a subsidiary and the absorption-type split of JT’s...

Shionogi & Co., Ltd. plans to invest USD 2.125 billion (approximately JPY 334.793 billion) to increase its voting rights ratio in ViiV Healthcare Ltd. from 10.0% to 21.7%, thereby achieving application as an equity-method affiliate (to be acquired by the end of March 2026).

Shionogi & Co., Ltd. has obtained domestic manufacturing and marketing approval for the depression treatment drug "Zazvey® Capsules 30mg" in Japan and has launched it in the market as a novel mechanism of action treatment with rapid onset.

Shionogi & Co., Ltd. has obtained domestic manufacturing and marketing approval for the depression treatment drug 'Zavege® Capsules 30mg' in Japan and has started market launch as a novel mechanism of action treatment with rapid efficacy.

Shionogi has acquired the Edaravone business for the treatment of amyotrophic lateral sclerosis and other conditions from Tanabe Pharma, obtaining full global rights. The business is expected to contribute to revenue and profits from fiscal year 2026 onward.

As of September 1, 2025, Shionogi & Co., Ltd. completed the acquisition of all shares of Torii Pharmaceutical Co., Ltd., making it a wholly-owned subsidiary.